What is the mechanism by which abemaciclib (a cyclin‑dependent kinase 4/6 inhibitor) causes macrocytosis and a modest increase in serum creatinine in a patient with breast‑cancer remission?

Mechanism of Abemaciclib-Induced Macrocytosis and Creatinine Elevation

Creatinine Elevation: Pseudo-Renal Impairment

Abemaciclib causes a reversible increase in serum creatinine by inhibiting renal tubular secretion transporters—specifically organic cation transporter 2 (OCT2), multidrug and toxin extrusion protein 1 (MATE1), and MATE2-K—without causing actual kidney damage or reducing glomerular filtration rate. 1

Mechanism of Creatinine Changes

• Transporter inhibition: Abemaciclib blocks OCT2, MATE1, and MATE2-K in the proximal renal tubules, preventing normal creatinine secretion into urine 1
• Preserved kidney function: Clinical studies demonstrate that measured glomerular filtration rate (using iohexol clearance), serum cystatin C, and urinary kidney injury markers (NGAL, KIM-1) remain unchanged despite creatinine elevation 1
• Magnitude and timing: Creatinine typically increases 15-40% above baseline, with median onset at 21.5-42 days after treatment initiation 2, 3
• Reversibility: Creatinine values return to baseline after abemaciclib discontinuation 2

Clinical Implications

This is pseudo-renal failure, not true nephrotoxicity. The elevated creatinine reflects reduced tubular secretion rather than decreased kidney filtration capacity 4. However, true acute kidney injury can occur in specific contexts:

• Dehydration-related: Abemaciclib causes significant gastrointestinal toxicity (diarrhea), which can lead to volume depletion and prerenal azotemia 5
• Rare intrinsic injury: Isolated cases of acute tubular necrosis and tubulointerstitial nephritis have been documented on biopsy, though these are uncommon 5

Your patient's cystatin C result will clarify whether the creatinine increase from 0.9 to 1.0 mg/dL represents true filtration decline or transporter inhibition alone. If cystatin C-based GFR remains stable, no intervention is needed beyond monitoring.

---

Macrocytosis: Cell Cycle Disruption

The mechanism by which abemaciclib causes macrocytosis (MCV ~110 fL) is not explicitly defined in the FDA label or published literature, but likely results from CDK4/6 inhibition affecting erythroid progenitor cell cycle progression and maturation in the bone marrow.

Proposed Mechanism

• CDK4/6 inhibition: Abemaciclib blocks cyclin-dependent kinases 4 and 6, which normally promote cell cycle progression from G1 to S phase by phosphorylating retinoblastoma protein (Rb) 6
• Erythroid impact: When CDK4/6 activity is suppressed, erythroid precursors may undergo fewer cell divisions during maturation, resulting in larger-than-normal red blood cells entering circulation
• Bone marrow effects: The drug causes senescence and altered proliferation patterns in rapidly dividing cells 6, which would include erythroid lineage cells

Clinical Context

• Common finding: Macrocytosis appears to be a class effect of CDK4/6 inhibitors, though specific incidence data are not well-characterized in the literature
• Associated cytopenias: Your patient's leukopenia (WBC 2.5), lymphopenia, and previous neutropenia are expected on-target effects of CDK4/6 inhibition in hematopoietic cells
• Improvement pattern: Your patient's MCV has decreased from 114 to 110, and hemoglobin has improved to 10.8 g/dL, suggesting partial adaptation or recovery

Differential Considerations

While abemaciclib is the likely cause, verify that:

• Vitamin B12 is adequate (you note this is normal)
• Folate status is sufficient (the adrenal support injection contains folic acid, which may help)
• Thyroid function is normal (you're planning thyroid testing after pausing biotin-containing ASI)

---

Monitoring Recommendations

For creatinine elevation:

• Use cystatin C-based GFR estimation for accurate kidney function assessment 2, 4
• Monitor for dehydration given abemaciclib's gastrointestinal effects
• Avoid unnecessary dose adjustments of concomitant renally-cleared medications based on creatinine alone 2

For macrocytosis:

• Continue monitoring CBC with differential every 2-3 months
• Discuss with oncology whether the degree of macrocytosis and cytopenias warrant dose modification (though current values appear manageable)
• Ensure adequate B12 and folate support

The combination of pseudo-renal impairment and macrocytosis represents expected pharmacologic effects of abemaciclib rather than true organ toxicity, though vigilance for true kidney injury (via dehydration or rare intrinsic damage) and clinically significant cytopenias remains essential.